Thrombocytosis

New England Journal of Medicine

Volumn 350, Issue 12, 2004, Pages 1211-1219

  Schafer, Andrew I ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALKYLATING AGENT; ALPHA INTERFERON; ANAGRELIDE; ANTITHROMBOCYTIC AGENT; CYTOKINE; GROWTH FACTOR; HYDROXYUREA; QUINAZOLINE DERIVATIVE; RETINOIC ACID; VINCRISTINE;

ACUTE LEUKEMIA; ANEMIA; BLEEDING; CLINICAL FEATURE; CLONAL VARIATION; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; FLUID RETENTION; HEADACHE; HEART ARRHYTHMIA; HEART FAILURE; HEART PALPITATION; HUMAN; INOTROPISM; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TERATOGENICITY; THROMBOCYTE COUNT; THROMBOCYTHEMIA; THROMBOCYTOSIS; VASODILATATION;

ASPIRIN; CLONE CELLS; DIAGNOSIS, DIFFERENTIAL; HUMANS; HYDROXYUREA; INTERFERON-ALPHA; PLASMAPHERESIS; PLATELET AGGREGATION INHIBITORS; QUINAZOLINES; THROMBOCYTHEMIA, HEMORRHAGIC; THROMBOCYTOSIS;

EID: 1542615163     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMra035363     Document Type: Review

References (47)

1. Kaushansky K. Regulation of megakaryopoiesis. In: Loscalzo J, Schafer AI, eds. Thrombosis and hemorrhage. 3rd ed. Philadelphia: Lippincott Williams & Wilkins, 2003:120-39.
2. Wolber EM, Fandrey J, Frackowski U, Jelkmann W. Hepatic thrombopoietin mRNA is increased in acute inflammation. Thromb Haemost 2001;86:1421-4.
3. Wang JC, Chen C, Novetsky AD, Lichter SM, Ahmed F, Friedberg NM. Blood thrombopoietin levels in clonal thrombocytosis and reactive thrombocytosis. Am J Med 1998; 104:451-5.
4. Hsu HC, Tsai WH, Jiang ML, et al. Circulating levels of thrombopoietic and inflammatory cytokines in patients with clonal and reactive thrombocytosis. J Lab Clin Med 1999;134:392-7.
5. Folman CC, Ooms M, Kuenen BB, et al. The role of thrombopoietin in post-operative thrombocytosis. Br J Haematol 2001;114:126-33.
6. Ishiguro A, Suzuki Y, Mito M, et al. Elevation of serum thrombopoietin precedes thrombocytosis in acute infections. Br J Haematol 2002;116:612-8.
7. Kaser A, Brandacher G, Steurer W, et al. Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis. Blood 2001;98:2720-5.
8. Horikawa Y, Matsumura I, Hashimoto K, et al. Markedly reduced expression of platelet c-mpl receptor in essential thrombocythemia. Blood 1997;90:4031-8.
9. Li J, Xia Y, Kuter DJ. The platelet thrombopoietin receptor number and function are markedly decreased in patients with essential thrombocythaemia. Br J Haematol 2000; 111:943-53.
10. Mesa RA, Hanson CA, Li C-Y, et al. Diagnostic and prognostic value of bone marrow angiogenesis and megakaryocyte c-Mpl expression in essential thrombocythemia. Blood 2002;99:4131-7.
11. Teofili L, Pierconti F, Di Febo A, et al. The expression pattern of c-mpl in megakaryocytes correlates with thrombotic risk in essential thrombocythemia. Blood 2002; 100:714-7.
12. Schafer AI. Thrombocytosis and thrombocythemia. Blood Rev 2001;15:159-66.
13. Axelrad AA, Eskinazi D, Correa PN, Amato D. Hypersensitivity of circulating progenitor cells to megakaryocyte growth and development factor (PEG-rHu MGDF) in essential thrombocythemia. Blood 2000;96:3310-21.
14. Griesshammer M, Bangerter M, Sauer T, Wennauer R, Bergmann L, Heimpel H. Aetiology and clinical significance of thrombocytosis: analysis of 732 patients with an elevated platelet count. J Intern Med 1999; 245:295-300.
15. Buss DH, Cashell AW, O'Connor ML, Richards F II, Case LD. Occurrence, etiology, and clinical significance of extreme thrombocytosis: a study of 280 cases. Am J Med 1994;96:247-53.
16. Kondo T, Okabe M, Sanada M, et al. Familial essential thrombocythemia associated with one-base deletion in the 5′-untranslated region of the thrombopoietin gene. Blood 1998;92:1091-6.
17. Wiestner A, Schlemper RJ, van der Maas AP, Skoda RC. An activating splice donor mutation in the thrombopoietin gene causes hereditary thrombocythaemia. Nat Genet 1998;18:49-52.
18. Cazzola M, Skoda RC. Translational pathophysiology: a novel molecular mechanism of human disease. Blood 2000;95:3280-8.
19. Thiele J, Kvasnicka HM, Schmitt-Graeff A, Zankovich R, Diehl V. Follow-up examinations including sequential bone marrow biopsies in essential thrombocythemia (ET): a retrospective clinicopathological study of 120 patients. Am J Hematol 2002;70:283-91.
20. Takahashi H, Furukawa T, Hashimoto S, et al. 5q-syndrome presenting chronic myeloproliferative disorders-like manifestation: a case report. Am J Hematol 2000;64:120-3.
21. Liu E, Jelinek J, Pastore YD, Guan Y, Prchal JF, Prchal JT. Discrimination of polycythemias and thrombocytoses by novel, simple, accurate clonality assays and comparison with PRV-1 expression and BFU-E response to erythropoietin. Blood 2003;101:3294-301.
22. Shih LY, Lin TL, Lai CL, et al. Predictive values of X-chromosome inactivation patterns and clinicohematologic parameters for vascular complications in female patients with essential thrombocythemia. Blood 2002;100:1596-601.
23. Harrison CN, Gale RE, Machin SJ, Linch DC. A large proportion of patients with a diagnosis of essential thrombocythemia do not have a clonal disorder and may be at lower risk of thrombotic complications. Blood 1999;93:417-24.
24. Bazzan M, Tamponi G, Schinco P, et al. Thrombosis-free survival and life expectancy in 187 consecutive patients with essential thrombocythemia. Ann Hematol 1999;78:539-43.
25. Kesler A, Ellis MH, Manor Y, Gadoth N, Lishner M. Neurological complications of essential thrombocytosis (ET). Acta Neurol Scand 2000;102:299-302.
26. Wright CA, Tefferi A. A single institutional experience with 43 pregnancies in essential thrombocythemia. Eur J Haematol 2001;66:152-9.
27. Pearson TC. The risk of thrombosis in essential thrombocythemia and polycythemia vera. Semin Oncol 2002;29:Suppl 10:16-21.
28. Mesa RA, Silverstein MN, Jacobsen SJ, Wollan PC, Tefferi A. Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976-1995. Am J Hematol 1999;61:10-5.
29. Harrison CN. Current trends in essential thrombocythaemia. Br J Haematol 2002; 117:796-808.
30. Hoffman R. Quality of life issues in patients with essential thrombocythemia and polycythemia vera. Semin Oncol 2002;29: Suppl 10:3-9.
31. Cervantes F, Alvarez-Larran A, Talarn C, Gomez M, Montserrat E. Myelofibrosis with myeloid metaplasia following essential thrombocythaemia: actuarial probability, presenting characteristics and evolution in a series of 195 patients. Br J Haematol 2002;118:786-90.
32. Bernasconi P, Boni M, Cavigliano PM, et al. Acute myeloid leukemia (AML) having evolved from essential thrombocythemia (ET): distinctive chromosome abnormalities in patients treated with pipobroman or hydroxyurea. Leukemia 2002;16:2078-83.
33. Picardi M, Martinelli V, Ciancia R, et al. Measurement of spleen volume by ultrasound scanning in patients with thrombocytosis: a prospective study. Blood 2002;99:4228-30.
34. Aviram A, Blickstein D, Stark P, et al. Significance of BCP,-ABL transcripts in bone marrow aspirates of Philadelphia-negative essential thrombocythemia patients. Leuk Lymphoma 1999;33:77-82.
35. Emilia G, Marasca R, Zucchini P, et al. BCP-ABL rearrangement is not detectable in essential thrombocythemia. Blood 2001;97:2187-9.
36. Heller P, Kornblihtt LI, Cuello MT, Larripa I, Najfeld V, Molinas FC. BCR-ABL transcripts may be detected in essential-thrombocythemia but lack clinical significance. Blood 2001;98:1990.
37. Moliterno AR, Hankins WD, Spivak JL. Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera. N Engl J Med 1998;338:572-90.
38. Cortelazzo S, Finazzi G, Ruggeri M, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 1995;332:1132-6.
39. Finazzi G, Ruggeri M, Rodeghiero F, Barbui T. Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial. Br J Haematol 2000;110:577-83.
40. Liozon E, Brigaudeau C, Trimoreau F, et al. Is treatment with hydroxyurea leukemogenic in patients with essential thrombocythemia? An analysis of three new cases of leukemic transformation and review of the literature. Hematol Cell Ther 1997;39:11-8.
41. Sterkers Y, Preudhomme C, Lai JL, et al. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood 1998;91:616-22.
42. Hanft VN, Fruchtman SR, Pickens CV, Rosse WF, Howard TA, Ware RE. Acquired DNA mutations with in vivo hydroxyurea exposure. Blood 2000;95:3589-93.
43. Tomer A. Effects of anagrelide on in vivo megakaryocyte proliferation and maturation in essential thrombocythemia. Blood 2002; 99:1602-9.
44. Storen EC, Tefferi A. Long-term use of anagrelide in young patients with essential thrombocythemia. Blood 2001;97:863-6.
45. Jurado M, Deeg H, Gooley T, et al. Haemopoietic stem cell transplantation for advanced polycythaemia vera or essential thrombocythaemia. Br J Haematol 2001; 112:392-6.
46. Barbui T, Buelli M, Cortelazzo S, Viero P, De Gaetano G. Aspirin and risk of bleeding in patients with thrombocythemia. Am J Med 1987;83:265-8.
47. Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 2004;350:114-24.